Literature DB >> 35116383

Correlation between apparent diffusion coefficient and Ki-67 in different pathological types of lung cancer.

Hongna Ren1, Jianbing Ma1, Jia Wang1.   

Abstract

BACKGROUND: Computed tomography (CT) is common and valuable non-invasive method to evaluate proliferative activity in lung cancer; however, magnetic resonance (MR) is rarely used in lung cancer. To evaluate whether there were different expression levels of Ki-67 in different pathological types of lung cancer and the correlation between Ki-67 index and apparent diffusion coefficient (ADC) value.
METHODS: The clinical and pathological data of 165 patients with lung cancer confirmed by needle biopsy or surgery were retrospectively evaluated, among whom 54 underwent MR examination. The level of Ki-67 was tested using the international standard IHC 2-step method. Kruskal-Wallis H test was used to compare the different expression level of Ki-67 index of adenocarcinoma, squamous cell carcinoma, and small cell carcinoma, and the least significant difference (LSD) method was used for pair-group comparison. Spearman correlation coefficient was used to analyze the correlation between Ki-67 index and ADC value. All statistical tests were bilateral, and P<0.05 was considered statistically significant.
RESULTS: The median of Ki-67 index in adenocarcinoma, squamous cell carcinoma, and small cell carcinoma were 20 (10, 30), 40 (40, 60), and 70 (60, 80), respectively. There was a statistical difference in the expression level of Ki-67 index in the 3 different pathological types of lung cancer (H=103.762, P=0.000). In 54 cases of lung cancer with MR examination, there was a significant negative correlation between average ADC value and expression level of Ki-67 index (r=-0.506, P=0.000), while there was no correlation between ADC value and Ki-67 index in distinguishing different pathological types of lung cancer.
CONCLUSIONS: The expression level of Ki-67 index was different among different pathological types of lung cancer. The ADC value is correlated with Ki-67 index in lung cancer, which can be used to evaluate the proliferative activity of lung cancer. 2021 Translational Cancer Research. All rights reserved.

Entities:  

Keywords:  Ki-67 index; Lung cancer; diffusion weighted imaging (DWI); magnetic resonance (MR)

Year:  2021        PMID: 35116383      PMCID: PMC8798236          DOI: 10.21037/tcr-21-2515

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN: 2218-676X            Impact factor:   1.241


Introduction

Lung cancer is one of the most common malignant tumors in the world (1), and is associated with a low 5-year survival rate. The most important prognostic factor of lung cancer is local and distant metastasis. The nuclear protein, Ki-67, is an important index reflecting the proliferation status in lung cancer cells (2), and the Ki-67 proliferation index (PI) has been widely used as a marker of cell proliferation. Previous studies have shown that a high Ki-67 PI has a negative impact on disease-free survival and relapse-free survival (3,4). Although Ki-67 index can adequately reflect the metastasis and prognosis in lung cancer, the proliferative activity of lung cancer often needs to be evaluated by invasive surgery or biopsy. Currently, there are many imaging techniques for the diagnosis of lung cancer, such as X-ray, computed tomography (CT), positron emission tomography (PET) and magnetic resonance (MR) (5,6). Among them, diffusion weighted imaging (DWI) sequence of MR has been reported as useful for the differential diagnosis of malignant and benign tumors in the lung (7-10). In addition, 2 meta-analyses have also shown that DWI is useful for the evaluation of the node (N) factor of lung cancer (11,12). MR has higher sensitivity and accuracy in distinguishing the solid components or necrotic cystic areas of lung cancer than CT examination. Compared with CT, MR can provide more information about the components of the lesion by multi-sequence imaging, and is safer without radiation. Therefore, MR has been increasingly applied in the research of lung cancer in recent years.In this study, the correlation between Ki-67 index and apparent diffusion coefficient (ADC) value was analyzed to evaluate its feasibility and reliability in predicting the proliferative activity of lung cancer. In our study, a relatively large number of patients were included to verify the expression level of Ki-67 index in different pathological types of lung cancer. Comparing the correlation between Ki-67 index and ADC value, a relatively large number of patients were also enrolled for the MR examination, and there were relatively equal numbers of patients between the different groups in order to reduce the error. In addition, Ki-67 index was compared in the different pathological types of lung cancer. We present the following article in accordance with the MDAR reporting checklist (available at https://dx.doi.org/10.21037/tcr-21-2515).

Methods

This study was approved by the Ethics Committee of the First Hospital of Jiaxing (No.: LS2018-221), and the requirement for individual consent was waived by the committee due to retrospective nature of the study. All procedures performed in this study involving human participants were in accordance with the Declaration of Helsinki (as revised in 2013).

Patients

From March 2012 to June 2021, 165 patients with pathologically confirmed lung cancer (140 men and 25 women; age range, 44 to 88 years; mean age, 70 years) were recruited to this study. Pathological assessment revealed 47 adenocarcinomas, 58 squamous cell carcinomas, and 60 small cell carcinomas. None of the patients had received chemotherapy or radiotherapy prior to confirmation of their diagnosis. There were 57 patients who underwent MR examination. Among them, 3 patients were excluded owing to having received chemotherapy or targeted drugs before MR examination. Finally, 54 patients with a single solid tumor were included. The workflow of patient selection is shown in .
Figure 1

Workflow of patient selection.

Workflow of patient selection. The inclusion criteria were as follows: (I) patients with lung cancer confirmed by needle biopsy or surgery; (II) complete MR imaging data; (III) well-defined measurable areas of tumor tissue were displayed on MR images; (IV) immunohistochemistry was performed, and Ki-67 index was positive. The exclusion criteria were as follows: (I) MR examination had not been performed in our hospital; (II) the ADC value could not be measured on MR images; (III) had already received chemotherapy or other treatments before MR examination.

Image acquisition

All MR images were obtained by 3.0-T unit (GE Discovery MR750; GE Healthcare, Waukesha, WI, USA) equipped with an 8-channel body coil. A supine position was adopted and breathing exercises were carried out before scan. The scanning sequences included T1WI [repetition time (TR) 600–900 ms, time to echo (TE) 5.8 ms, layer thickness 6.0 mm, layer spacing 1.2 mm, horizontal axis], T2WI (TR 6,000–8,000 ms, TE 80 ms, layer thickness 6.0 mm, layer spacing 1.2 mm), and DWI (respiratory navigation single excitation plane echo imaging; B value was 0, 100, 200, 500, 600, 800, and 1,000 s/mm, respectively). Ultimately, the B value of 500 s/mm was selected for image analysis.

Image analysis

On the ADW 4.2 post-processing workstation (GE Healthcare, USA), the Function Tool software was used for image post-processing to evaluate DWI signal intensity characteristics and measure ADC value. The region of interest (ROI) selection was as follows: the area with the largest and most uniform signal intensity of the lesion was selected for measurement (signal intensity was taken the mean value of 3 measurements). For the more homogeneous lesions, the ROI included more than 50% of the maximum diameter of the lesion. For the inhomogeneous lesions with cavities, liquefying, or necrotic components, multiple smaller areas of ROI were selected to calculate the mean value (), including the center area of the maximum signal intensity as far as possible. The range of ROI was 20–500 mm2. The data were analyzed by 3 radiologists experienced in chest MR imaging diagnosis using a double-blind method, and the mean value was obtained.
Figure 2

Small cell carcinomas in a 75-year-old man who underwent MR examination. Comparing the DWI image (A-C, circle and numbers), three areas of ROI were selected on ADC map (D-F, circle and numbers), and the area of cavities, liquefying, or necrotic components were avoided. The area range of ROI was 88 to 217 mm2 (A-F circle and numbers). Immunohistochemistry map showed the high Ki-67expression (original magnification, ×200) (Ki-67=90%) (G). ROI, region of interest; ADC, apparent diffusion coefficient; DWI, diffusion weighted imaging.

Small cell carcinomas in a 75-year-old man who underwent MR examination. Comparing the DWI image (A-C, circle and numbers), three areas of ROI were selected on ADC map (D-F, circle and numbers), and the area of cavities, liquefying, or necrotic components were avoided. The area range of ROI was 88 to 217 mm2 (A-F circle and numbers). Immunohistochemistry map showed the high Ki-67expression (original magnification, ×200) (Ki-67=90%) (G). ROI, region of interest; ADC, apparent diffusion coefficient; DWI, diffusion weighted imaging.

Pathologic reviews

The expression level of Ki-67 was routinely evaluated by 2 pathologists (with 14 and 15 years of experience in phymatology, respectively) using typical tumor samples collected from the patients. Routine hematoxylin and eosin (HE) and immunohistochemical (IHC) staining were performed and recorded. The level of Ki-67 was tested using the international standard IHC 2-step method, and defined as positive when the nucleus was stained brown. The Ki-67 index was expressed using the percentage (%) of positive cells under low-to high-power microscopy.

Statistical analysis

Statistical analysis was carried out using SPSS 26.0 software (IBM Corp., Armonk, NY, USA). For quantitative variables, those with normal distribution were represented by x±s, and those with non-normal distribution were represented by median (P25, P75). Kruskal-Wallis H test was used to compare the expression level of Ki-67 index of adenocarcinoma, squamous cell carcinoma, and small cell carcinoma. The variables were ranked for pairwise comparison between groups, and the rank was used as the measurement variable. The least significant difference (LSD) method was used for pair-group comparison. The relationship between ADC value and Ki-67 index was calculated by Spearman’s coefficient. The difference was considered statistically significant when P<0.05.

Results

A total of 165 patients with single lesions of lung cancer were included in our study. The clinical characteristics are summarized in . The median age was 70 years (range: 44 to 88 years) and the majority of patients were male (85%). Among the types of tumors, 47 were adenocarcinomas (27%), 58 were squamous cell carcinomas (35%), and 60 were small cell carcinomas (36%). The average Ki-67 index was 54.8% (range: 5% to 90%).
Table 1

Clinical characteristics of patients with lung cancer

Parameters Number of patients (n=165)%
Age (years)
   Average70
   Range44–88
Gender
   Male14085
   Female2515
Type
   Adenocarcinoma4727
   Squamous cell carcinoma5835
   Small cell carcinoma6036
Ki-67 index (%)
   Average54.8
   Range5–90
A total of 54 patients underwent MR examination, among whom there were 17 adenocarcinomas (31%), 17 squamous cell carcinomas (31%), and 20 small cell carcinoma (38%). The mean tumor diameter was 37.7 mm (range: 22.1 to 74.5 mm). The different expression level of Ki-67 in the 3 pathological types of lung cancer are shown in and (H=103.762, P=0.000). Small cell carcinoma had the highest expression level and adenocarcinoma had the lowest.
Table 2

Comparison of Ki-67 index among 3 groups of lung cancer

GroupNumber of patientsKi-67 index (%)
Adenocarcinoma4720 (10, 30)
Squamous cell carcinoma5840 (40, 60)
Small cell carcinoma6070 (60, 80)
Overall comparisonH=103.762P=0.000
Post Hoc (LSD, P)Adenocarcinoma vs. squamous cell carcinomaP=0.000
Adenocarcinoma vs. small cell carcinomaP=0.000
Squamous cell carcinoma vs. small cell carcinomaP=0.000

LSD, least significant difference.

Figure 3

Distribution of Ki-67 index of 3 groups of lung cancer (H=103.762, P=0.000).

LSD, least significant difference. Distribution of Ki-67 index of 3 groups of lung cancer (H=103.762, P=0.000). The correlation detected between Ki-67 index and ADC value of lung cancer is summarized in . The average ADC value of the 3 types lung cancer was (1.183±0.466)×10-6 mm2/s. The average ADC values of adenocarcinoma, squamous cell carcinoma, and small cell carcinoma were (1.299±0.451)×10-6 mm2/s, (1.232±0.437)×10-6 mm2/s, and (1.042±0.317)×10-6 mm2/s, respectively. The average ADC value of the 3 types of lung cancer was negatively correlated with Ki-67 index (r=−0.506, P=0.000). The ADC value correlated moderately with Ki-67 index (). There was no correlation between ADC value and Ki-67 index in the case of distinguishing the pathological types.
Table 3

Correlation between Ki-67 index and ADC value in lung cancer

Parameter (ADC value)Ki-67 index
AverageAdenocarcinomaSquamous cell carcinomaSmall cell carcinoma
r−0.506−0.294−0.375−0.382
P value0.0000.2530.1380.107

ADC, apparent diffusion coefficient.

Figure 4

The average Ki-67 index of lung cancer was moderately correlated with ADC (r=−0.506, P=0.000<0.05). ADC, apparent diffusion coefficient.

ADC, apparent diffusion coefficient. The average Ki-67 index of lung cancer was moderately correlated with ADC (r=−0.506, P=0.000<0.05). ADC, apparent diffusion coefficient.

Discussion

The nuclear protein Ki-67 is a monoclonal antibody located in the nucleus, which is related to cell mitosis and cycle, and can reflect the proliferation ability of tumor cells. The expression level of Ki-67 is different in benign and malignant tumors. Similarly,it is different in the pathological subtype of lung cancer. As the expression level of Ki-67 index increases, the proliferative activity of lung cancer increases, and the prognosis and survival rate decrease (5,9-11). The DWI technology can be used for the measurement and imaging of water molecular diffusion in vivo in a non-invasive form, and indirectly reflect the information of tissue structure and cell density at a micro molecular level. ADC value is used to represent the diffusion velocity and range of different directional water of DWI, which are mostly represented by ADC diagrams and values. ADC value mainly reflects the diffusion amplitude and signal level of water molecules, while is opposite to DWI. By quantifying the movement of water molecules, ADC value can indirectly reflect tumor cell density, peripheral invasion status and nucleo-plasma ratio to some extent. Due to the small extracellular space of tumor tissues, the diffusion of water molecules is limited, resulting in low ADC value. In terms of the choice of B value, previous studies have suggested that when the B value is 500 s/mm, it is less affected by other factors such as perfusion (7,12,13). So, this value was also used in this study. In this study, there were differences in the expression level of Ki-67 index among different pathological types of lung cancer, the average value of Ki-67 index in small-cell carcinoma was the highest, and it was the lowest in adenocarcinoma. This suggested that the division rate and count of tumor cells were different in different pathological types of lung cancer. The count of tumor cells of squamous cell carcinoma and small cell lung cancer were higher than that of adenocarcinoma. At the same time, this study analyzed whether there was statistical difference in the expression level of Ki-67 index among 3 different pathological types of lung cancer. Our results showed that there was a statistical difference in the expression level of Ki-67 index in patients with 3 different pathological types of lung cancer (H=103.762, P=0.000). The results are similar to those reported by previous researchers (14). It also indicates that the participants in our study are suitable for further study of the correlation analysis between Ki-67 index and image features. Previous studies have basically focused on correlation analysis between Ki-67 index and CT signs or enhancement features, which has detected a certain correlation between the Ki-67 index with CT signs or enhancement features (15,16). However, there have been few studies on the comparison of Ki-67 index and MR signs. In terms of comparing the correlation between Ki-67 index and ADC value in different pathological types in lung cancer, our results showed that the average ADC value of adenocarcinoma was the highest, and it was lowest in small cell carcinoma. This study showed that there was a moderately negative correlation between average ADC value and Ki-67 index without distinguishing the pathological types. However, this correlation had also been confirmed in other solid tumors, such as breast cancer and glioma (17,18). Therefore, this study indicates that ADC value can indirectly reflect the proliferation situation of Ki-67 index in lung cancer. The higher the ADC value, the lower the cell proliferation activity. By comparing the correlation between Ki-67 index and ADC value in distinguishing pathological types of lung cancer, this study showed that there was no statistical difference. However, there have been few comparisons between different types of lung cancer and Ki-67 index in previous literatures based on MR examination. Most studies have been based on CT imaging features (19). In addition, the results of our study may be subject to the small number of participants and fewer cases of lung cancer targeted at the same stage. Therefore, further study should be carried out in a larger sample according to the same stage of lung cancer. Compared to CT, MR examination has some advantages in evaluating the proliferation activity of lung cancer, such as the internal structure (solid and necrotic areas) of the tumor can be showed more clearly, the proliferative activity of the tumor is measured more accurately. In addition, it has certain advantages in showing the lymph nodes of hilum and mediastinum. However, there are some disadvantages of MR examination, such as long scanning time, high cost and small lesions of the lung cannot be showed clearly. Overall, there is more value in assessing the proliferative activity of lung cancer of MR examination. This study had several limitations. First, it was a retrospective study in a single-center. Second, the sample size of patients who underwent MR examination was relatively small. Third, the measurement results may have been affected to a certain extent because of the lack of unified measurement standards (ROI size, location, etc.). Finally, our study was not based on the same staging of lung cancer.

Conclusions

As shown in our study, ADC value is expected to be the imaging indicators for predicting the expression level of Ki-67 index in lung cancer, and as an important imaging basis for the prediction of invasion and prognosis in lung cancer.
  18 in total

1.  Diffusion-weighted imaging is superior to positron emission tomography in the detection and nodal assessment of lung cancers.

Authors:  Katsuo Usuda; Xi-Tong Zhao; Motoyasu Sagawa; Munetaka Matoba; Yasuaki Kuginuki; Mitsuru Taniguchi; Yoshimichi Ueda; Tsutomu Sakuma
Journal:  Ann Thorac Surg       Date:  2011-06       Impact factor: 4.330

2.  Non-Gaussian diffusion MR imaging of glioma: comparisons of multiple diffusion parameters and correlation with histologic grade and MIB-1 (Ki-67 labeling) index.

Authors:  Ren Yan; Pang Haopeng; Feng Xiaoyuan; Wu Jinsong; Zhang Jiawen; Yao Chengjun; Qiu Tianming; Xiong Ji; Sheng Mao; Ding Yueyue; Zhang Yong; Luo Jianfeng; Yao Zhenwei
Journal:  Neuroradiology       Date:  2015-10-22       Impact factor: 2.804

3.  Can diffusion-weighted imaging be used as a reliable sequence in the detection of malignant pulmonary nodules and masses?

Authors:  Lian-Ming Wu; Jian-Rong Xu; Jia Hua; Hai-Yan Gu; Jie Chen; E M Haacke; Jiani Hu
Journal:  Magn Reson Imaging       Date:  2012-08-16       Impact factor: 2.546

4.  Is diffusion-weighted magnetic resonance imaging superior to positron emission tomography with fludeoxyglucose F 18 in imaging non-small cell lung cancer?

Authors:  Yasuomi Ohba; Hiroaki Nomori; Takeshi Mori; Koei Ikeda; Hidekatsu Shibata; Hironori Kobayashi; Shinya Shiraishi; Kazuhiro Katahira
Journal:  J Thorac Cardiovasc Surg       Date:  2009-03-29       Impact factor: 5.209

5.  Value of Ki-67 and computed tomography in the assessment of peripheral lung adenocarcinoma.

Authors:  Cheng Chen; Wei-Dong Zhu; Xiao-Hui Zhang; Ye-Han Zhu; Jian-An Huang
Journal:  Br J Biomed Sci       Date:  2016       Impact factor: 3.829

6.  The Diagnostic Value of MR Imaging in Determining the Lymph Node Status of Patients with Non-Small Cell Lung Cancer: A Meta-Analysis.

Authors:  Jurgen Peerlings; Esther G C Troost; Patricia J Nelemans; David C P Cobben; Johannes C J de Boer; Aswin L Hoffmann; Regina G H Beets-Tan
Journal:  Radiology       Date:  2016-04-25       Impact factor: 11.105

7.  Performance of DWI in the Nodal Characterization and Assessment of Lung Cancer: A Meta-Analysis.

Authors:  Guohua Shen; Shuang Hu; Houfu Deng; Anren Kuang
Journal:  AJR Am J Roentgenol       Date:  2015-11-20       Impact factor: 3.959

8.  Synchronous multiple lung cancers presenting as multifocal pure ground glass nodules: are whole-body positron emission tomography/computed tomography and brain enhanced magnetic resonance imaging necessary?

Authors:  Meng Li; Yuan Wan; Li Zhang; Li-Na Zhou; Zhuo Shi; Rui Zhang; Yan-Lei Hou; Ning Wu
Journal:  Transl Lung Cancer Res       Date:  2019-10

9.  Ki-67 as a prognostic marker in early-stage non-small cell lung cancer in Asian patients: a meta-analysis of published studies involving 32 studies.

Authors:  Song Wen; Wei Zhou; Chun-Ming Li; Juan Hu; Xiao-Ming Hu; Ping Chen; Guo-Liang Shao; Wu-Hua Guo
Journal:  BMC Cancer       Date:  2015-07-15       Impact factor: 4.430

10.  Correlation between radiomic features based on contrast-enhanced computed tomography images and Ki-67 proliferation index in lung cancer: A preliminary study.

Authors:  Bodong Zhou; Jie Xu; Ye Tian; Shuai Yuan; Xubin Li
Journal:  Thorac Cancer       Date:  2018-08-01       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.